Why the study?
AF increases the risk of stroke and death, and although OACs are highly effective, DOACs became available worldwide in 2011, motivating evaluation of 10-year trends in antithrombotic therapy and outcomes.
Does the transition to direct oral anticoagulants (DOACs) and updated guideline-directed care improve clinical outcomes in Japanese patients with atrial fibrillation?
Does the transition to direct oral anticoagulants (DOACs) and updated guideline-directed care improve clinical outcomes in Japanese patients with atrial fibrillation?
The increasing adoption of DOACs over a 10-year period in Japan was associated with a significant decline in the incidence of stroke, systemic embolism, and all-cause death among patients with atrial fibrillation.
BACKGROUND: Atrial fibrillation (AF) increases the risk of stroke and death. Oral anticoagulants (OAC) are highly effective in reducing the risk of stroke, and direct oral anticoagulants (DOAC) became available worldwide in 2011. METHODS AND RESULTS: score 2.03 vs. 2.04, and HAS-BLED score 1.67 vs. 1.77, respectively). CONCLUSIONS: Over the past 10 years, there has been a major transition in antithrombotic therapy and a decline in the incidence of adverse events in AF patients.
No takes yet. Share an insight, caveat, or question.
Akao et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: